PODD
Insulet Corporation
Health Care · Health Care Equipment · US
$153.22
Data: 2026-05-15
✓ ETHICAL PASS

MODERATE MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$10.3B
Total market value of the company
Trailing P/E
34.76
Premium valuation
Forward P/E
18.45
Based on estimated future earnings — lower means cheaper
Rev Growth
+33.9%
Year-over-year revenue change
Profit Margin
10.4%
How much profit the company keeps from each dollar of revenue
ROE
23.0%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$250.13
+63% from current price — median analyst estimate
Recommendation
BUY
Consensus view from 24 analysts covering this stock
About Insulet Corporation

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

https://www.insulet.com

Country: United States Employees: 5,400 Industry: Medical Devices
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
29.8% PASS
Debt must be below 33% of total assets
Cash Ratio
0.0% PASS
Interest-bearing cash below 33% of assets
Receivables
38.5% PASS
Receivables below 49% of assets
Revenue Purity
1.3% PASS
Non-compliant revenue below 5% — any excess requires purification
Valuation
Fair Value Est.
$241.94
What our model estimates this business is worth per share
Margin of Safety
36.7%
Trading below fair value — margin of safety exists
Rating
OPPORTUNITY
Overall assessment combining ethics, valuation, and quality
Percentile
96.5th
Ranks in the top 4% of our 13,571 screened universe
Ethical Score
75.9
Valuation Score
73.0
Quality Score
77.0
Combined
72.1

Trading at $149 against a fair value of $242, a 39% discount. Moderate competitive position. Passes all ethical screens. Ranks better than 90% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
DISTRIBUTION
Smart money appears to be selling into strength — caution
Sharpe Ratio
-0.001
Returns do not compensate for the risk — negative edge
Kelly Fraction
0.0000
No positive edge detected — the data suggests staying out
Calmar Ratio
-0.121
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-7.1%
Historical annualised return based on price data
Max Drawdown
-58.2%
Largest peak-to-trough decline — the worst it has been
HMM State
CRISIS
Elevated risk detected — extreme caution warranted
Days in State
18
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
1.20
Moves slightly more than the broader market
52W High
$354.88
57% below the year high
52W Low
$145.59
5% above the year low
Avg Volume
1,220,966
Average daily shares traded — higher means easier to buy and sell
Short Ratio
2.8
Days it would take all short sellers to cover — higher means more crowded
Short % Float
4.8%
Low short interest — limited bearish positioning
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$4.28
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
0.78
Moderate leverage — manageable
Current Ratio
2.49
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
1.49
Like current ratio but excludes inventory — stricter test
Gross Margin
71.0%
Revenue left after cost of goods — higher means pricing power
Operating Margin
16.0%
Profit from core operations before interest and tax
Free Cash Flow
$253M
Positive — the business generates more cash than it spends
Revenue (TTM)
$2.9B
Total revenue over the last 12 months
Net Income
$303M
Profitable — the bottom line is positive
Analyst Coverage
Analysts
24
Target High
$360.00
Target Median
$250.13
Target Low
$175.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

55
NEUTRAL
Mixed insider activity. 0 purchases and 0 sales in the last 90 days — no clear directional signal. Politicians have been buying this name.
Date Insider Title Type Shares Value
2026-05-20 HOPFIELD JESSICA Director 1,660 —
2026-05-20 HUFFINES ROBERT LUTHER Director 1,660 —
2026-05-20 FREDERICK WAYNE A.I. Director 1,660 —
2026-05-20 MINOGUE MICHAEL R Director 1,660 —
2026-04-01 PANOS MICHAEL Officer 2,777 —
2026-03-31 HUFFINES ROBERT LUTHER Director 111 $23,292
2026-02-25 MINOGUE MICHAEL R Director 2,030 $499,847
2026-02-24 KAPPLES JOHN W. General Counsel 1,885 —
2026-02-24 BENJAMIN ERIC Chief Operating Officer 3,822 —
2026-02-24 MCEVOY ASHLEY Chief Executive Officer 10,046 —
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Political Trading Activity

Congressional trading disclosures involving this instrument

Date Politician Party Type Amount
2026-04-13 Ro Khanna Democrat Purchase 1K–15K
Source: Congressional disclosure filings. View all political trades at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.